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The WHO guidelines on evaluating biosimilar products represent an important step forward in the global
harmonization of biosimilar1 products regulation, and provide clear guidance for regulatory bodies and
industry. They conﬁrm the key principles of biosimilarity, namely stand alone manufacturing process
development and demonstrated comparability, which are described in many existing regional guidelines
for biosimilars. Based on the premise that companieswhich have developed capabilities for the production
of safe and efﬁcacious recombinant biopharmaceuticals also have the foundation and tools available to
make safe and efﬁcacious biosimilars, the guidelines provide industry with clear direction on how to
actually do so. Finally, when applying the WHO guidelines, it should be considered that the experience
gained by industry and regulators when evaluating manufacturing process changes of originator products
can be leveraged and directly applied to the development and approval of biosimilar products.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Since the mid 1990s, when companies started to develop their
own versions of existing recombinant biotherapeutic products, the
question of how to regulate these so-called biosimilar products has
been intensively discussed by stakeholders from industry and
agencies. It quickly became apparent that the traditional generic
pathway cannot be utilized for these products. The EU discussed
scientiﬁc concepts with industry and academics, while at the same
time developing a comprehensive set of guidelines, which came
into force in 2005 [1] and 2006 [2,3]. Other regions followed as
described below.
In 2007, the WHO also started to work on guidelines to assist
regulatory agencies globally with the key principles governing the
regulation of biosimilar products. The situation at the WHO was
complicated due to inconsistencies among the national agencies in
the level of comparability of important product characteristics they
required for approving alternate versions of existing recombinant
biotherapeutics. From the global perspective, we are therefore
confronted with a wide range of products. At the positive end areAustria.
bbreviation and synonym for
s)’.
ll rights reserved. The World Healthbiosimilars as deﬁned in the WHO guidelines, which are fully
comparable to their reference products. At the other end is a range
of alternate products with a varying but insufﬁcient level of
comparability. The latter may share the amino acid sequence with
an originator product, but are not comparable in other important
factors such as glycosylation, purity proﬁles or biological activity.
The WHO guidelines were ﬁnalized in 2009 [4] and provide much
needed consistency in this challenging situation. They ﬁll an
important gap in the global regulatory set-up, clarify terms and
help regulators, as well as industry, to provide safe and efﬁcacious
biosimilar products.2. Considerations for implementing the WHO guidelines
Recombinant biologics are complex molecules and, although we
can characterize them to a very high level using existing sophisti-
cated analytical tools, the manufacturing process usingmammalian
cells induces some variability in production that precludes making
identical batches of product or identical copies, as with synthetic
small molecule drugs. In addition, due to instances of immunoge-
nicity responses in originator products, development of biosimilars
generally requires data going beyond analytical characterization
and nonclinical testing to demonstrate clinical comparability and
also lack of unusual immunogenicity signals. Therefore theOrganization has granted the Publisher permission for the reproduction of this article.
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for a generic drug and also requires clinical studies different and
beyond a generic type bioequivalence study. In this context the key
question is to what extent the existing experience of an originator
product can be leveraged for the development and licensing of
a fully comparable biosimilar product.
The biosimilar concept laid out in the WHO guidelines is based
on a complete stand alone development of the manufacturing
process that produces a product with demonstrated comparability
to the reference product. WHO conﬁrms that highly comparable
quality justiﬁes an abbreviated nonclinical and clinical data
package. For example complete toxicity studies or dose ﬁnding
phase II studies could be waived. This being said, WHO guidelines
recognize that the nonclinical and clinical studies generally should
be done in a comparative manner using the reference product as
a control. Successful conﬁrmation of biosimilarity at the product
quality, preclinical and clinical levels including a comparative phase
III study would allow for approval of the biosimilar in that indica-
tion, as well as extrapolation of approval to all other indications of
the originator product. Since even small changes of a biological
product can alter the safety and/or the efﬁcacy proﬁle, those bio-
logic products that are not comparable to a reference product
would not be considered as biosimilar products, but would more
aptly be described as new biological entities. The WHO guidelines
help to clarify the difference between a biosimilar and a new bio-
logical entity, although the latter may have the same amino acid
sequence as a reference product. Any product in between does not
ensure a comparable product and could compromise the risk-
beneﬁt ratio of the established originator if used as a biosimilar.
The principles of the WHO guidelines, therefore, help industry in
designing a development strategy. The manufacturer can decide
whether to follow a biosimilar strategy in compliance with the
WHO guidelines, or to take the amino acid sequence of the origi-
nator product and follow a development program that results in
a new biological entity.
The biosimilar industry is generally in favor of global regulatory
standards, as most companies intend to market their products
outside their home country. From this perspective, the WHO
guidelines are a critical step forward in the direction of global
development. Not only can these guidelines support emerging
regulations in many regions, they also share the same key princi-
ples as already laid down in existing region-speciﬁc biosimilar
guidelines such as in the EU, Japan, Canada, Singapore, Malaysia,
and Republic of Korea (as well as countries that have adopted the
EU guidelines, such as Australia or Switzerland).
3. How difﬁcult is it to make a biosimilar?
At earlier WHO consultation meetings the question was raised
whether the WHO is setting the standard beyond the industry’s
existing skill-set to make biosimilars. However, the EU has already
approved biosimilar products, which also comply with the WHO
guidelines, since 2006, including several erythropoietins that
contain highly complex and heterogeneous glycan structures. This
real biosimilar market experience of more than four years, with
a demonstrated safety proﬁle consistent with the originator prod-
ucts, unequivocally demonstrates the industry’s capabilities for
making biosimilars. Developing them requires systematic and tar-
geted optimization of the manufacturing process to yield
a comparable product. As relevant quality attributes are usually
dependent on the interaction of many process parameters, such
optimization generally requires proper multivariate designs to be
successful. However, the tools needed to implement such studies
are now more commonly used as industry increasingly follows the
concepts of ‘Quality by Design’ as described in the ICH guidelinesICH Q8, Q9 and Q10 [5e7]. Therefore, any company that is able to
develop and manufacture safe and effective recombinant bio-
pharmaceuticals has all the tools available to make biosimilar
products. In essence, the entrance hurdle for developing and
manufacturing a biosimilar corresponds to the capability for
making recombinant therapeutics in general. There is no doubt
that, compared to an originator development program, the target-
directed development of a biosimilar needs more time in the early
development phase, for cell line optimization, process develop-
ment and the puriﬁcation process. However, this increased effort
can be offset by an abbreviated nonclinical and clinical develop-
ment program and the possibility of extrapolation to the multiple
indications of the reference product.
4. What can industry and regulators learn from existing
experience when managing process manufacturing changes?
The WHO guidelines provide globally acceptable principles for
licensing biosimilar products but are not prescriptive at the low-
level detail level. When applying the WHO guidelines, it is there-
fore also important to utilize scientiﬁc knowledge, for example,
experience from manufacturing process changes in the life cycle of
originator products, which are a common reality in the bio-
pharmaceutical industry. Originator product manufacturing
processes undergo changes during their life cycle for a variety of
reasons including process scale up and transfers to alternative
manufacturing sites [8]. Consequently, during changes in the
manufacturing process certain quality attributes are likely to
change. Since the dawn of recombinant biotherapeutics approxi-
mately 30 years ago, agencies and industry have gained substantial
experience in dealing with these changes. They are accepted only
based on demonstrated comparability of the pre- and post-change
product and on scientiﬁc evidence to exclude any negative impact
on clinical properties, following the principles laid down in guide-
line ICH Q5E [9]. This comparability evaluation typically requires
a detailed comparison of the product attributes, the knowledge of
structureefunction relationships and sometimes nonclinical and
clinical data. These comparability exercises provide experience and
a model for direct application to biosimilar development and
approval in linewith theWHO guidelines. For example, the changes
of the reference product over time offer a distribution of the quality
attributes, or “goalposts”, which can be used by regulators to judge
both comparability of a candidate biosimilar and extrapolation of
safety and efﬁcacy for the reference product, just as in a compara-
bility exercise following a manufacturing process change.
5. Conclusion
The WHO guidelines on Evaluation of Similar Biotherapeutic
Products represent an important step toward a harmonized regu-
lation of biosimilar products at a global scale. In essence, they are
based on the same principles as described in existing science-based
regional guidelines on biosimilar products, and will inform the
guidelines currently being developed by many other countries.
They help to harmonize regulations and provide clear guidance to
the biosimilar industry on how to design development programs
that deliver safe and efﬁcacious biosimilar products. With respect
to the detailed methodology of evaluating comparability between
a biosimilar candidate and its originator product, agencies and
industry can leverage the experience gained over the last 30 years
in evaluating comparability following process manufacturing
changes.
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